Nano spray-dried pyrazinamide-l-leucine dry powders, physical properties and feasibility used as dry powder aerosols

References

• Mitchison DA, Zhang Y. Recent developments in the study of pyrazinamide: an update. In: Donald PR, van Helden PD, eds. Progress in respiratory research, antituberculosis chemotherapy, Vol. 40. Basel: Karger; 2011:32–43
   Google Scholar
• World Health Organisation. Standard treatment regimens. In: Treatment of tuberculosis guidelines, 4th ed. Geneva: WHO Press; 2010:29–52
   Google Scholar
• Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharmaceut Res 2009;26:2401–2416
   PubMed Web of Science ®Google Scholar
• Chan JGY, Chan H-K, Prestidge CA, et al. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur J Pharm Biopharm 2013;83:285–292
   PubMed Web of Science ®Google Scholar
• Fiegel J, Garcia-Contreras L, Thomas M, et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharmaceut Res 2008;25:805–811
   PubMed Web of Science ®Google Scholar
• Mitchison DA, Fourie PB. The near future: improving the activity of rifamycins and pyrazinamide. Tuberculosis 2010;90:177–181
   PubMed Web of Science ®Google Scholar
• Rojanarat W, Nakpheng T, Thawithong E, et al. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv 2012;19:334–345
   PubMed Web of Science ®Google Scholar
• Misra A, Hickey AJ, Rossi C, et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011;91:71–81
   PubMed Web of Science ®Google Scholar
• Aquino RP, Prota L, Auriemma G, et al. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm 2012;426:100–107
   PubMed Web of Science ®Google Scholar
• Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010;392:1–19
   PubMed Web of Science ®Google Scholar
• Prota L, Santoro A, Bifulco M, et al. Leucine enhances aerosol performance of Naringin dry powder and its activity on cystic fibrosis airway epithelial cells. Int J Pharm 2011;412:8–19
   PubMed Web of Science ®Google Scholar
• Seville PC, Learoyd TP, Li HY, et al. Amino acid-modified spray dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol 2007;178:40–50
   Web of Science ®Google Scholar
• Chew NYK, Shekunov BY, Tong HHY, et al. Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci 2005;94:2289–2300
   PubMed Web of Science ®Google Scholar
• Glínski J, Chavepeyer G, Platten JK. Surface properties of aqueous solutions of L-leucine. Biophys Chem 2000;84:99–103
   PubMed Web of Science ®Google Scholar
• Rabbani NR, Seville PC. The influence of formulation components on the aerosolisation properties of spray-dried powders. J Contr Rel 2005;110:130–140
   PubMed Web of Science ®Google Scholar
• Schmid K, Arpagaus C, Friess W. Evaluation of the nano spray dryer b-90 for pharmaceutical applications. Pharm Dev Technol 2011;16:287–294
   PubMed Web of Science ®Google Scholar
• Srichana T, Suedee R, Srisudjai P. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie 2003;58:125–129
   PubMed Web of Science ®Google Scholar
• Meenach SA, Anderson KW, Hilt JZ, et al. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci 2013;49:699–711
   PubMed Web of Science ®Google Scholar
• Park CW, Li X, Vogt FG, et al. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int J Pharm 2013;455:374–392
   PubMed Web of Science ®Google Scholar
• Gong Z, Basir Y, Chu D, McCort-Tipton M. A rapid and robust liquid chromatography/tandem mass spectrometry method for simultaneous analysis of anti-tuberculosis drugs-ethambutol and pyrazinamide in human plasma. J Chromatogr B 2009;877:1698–1704
   PubMed Web of Science ®Google Scholar
• Nimbalkar MS, Pai SR, Pawar NV, et al. Free amino acid profiling in grain Amaranth using LC–MS/MS. Food Chem 2012;134:2565–2569
   PubMed Web of Science ®Google Scholar
• Li HY, Seville PC, Williamson IJ, Birchall JC. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J Gene Med 2005;7:343–353
   PubMed Web of Science ®Google Scholar
• Feng AL, Boraey MA, Gwin MA, et al. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm 2011;409:156–163
   PubMed Web of Science ®Google Scholar
• Najafabadi AR, Gilani K, Barghi M, Rafiee-Tehrani M. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with l-leucine. Int J Pharm 2004;285:97–108
   PubMed Web of Science ®Google Scholar
• Pham D-D, Fattal E, Ghermani NE, et al. Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients. Int J Pharm 2013;454:668–677
   PubMed Web of Science ®Google Scholar
• Castro RAE, Maria TMR, Evora AOL, et al. A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships. Cryst Growth Des 2010;10:274–282
   Web of Science ®Google Scholar
• Adalder TK, Sankolli R, Dastidar P. Homo- or heterosynthron? A crystallographic study on a series of new cocrystals derived from pyrazine carboxamide and various carboxylic acids equipped with additional hydrogen bonding sites. Cryst Growth Des 2012;12:2533–2542
   Web of Science ®Google Scholar